== Thermogenesis (KOOL) ==

Beiträge: 3
Zugriffe: 914 / Heute: 2
== Thermogenesis (KOOL) == HeinrichSchnitzel
HeinrichSchni.:

== Thermogenesis (KOOL) ==

 
05.01.12 14:47
#1

  Tach allerseits.

Es gibt sehr interessante News bezüglich Thermogenesis!

THERMOGENESIS ANNOUNCES APPROVAL OF AXP® BY INDIA MINISTRY OF HEALTH

(RANCHO CORDOVA, CA), January 4, 2012 —ThermoGenesis Corp. (NASDAQ: KOOL),
a leading supplier of innovative products and services that process and store adult stem cells, said today that India’s Ministry of Health has approved the AutoXpress® System (AXP), enabling the Company to initiate commercial sales of the product in India. The AXP is used for the
processing of stem cells from cord blood.
“We are pleased to have achieved registration for the AXP in India and will be working closely with Fenwal, Inc., our AXP distributor in the market, to begin the commercial launch of the device,” said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.
“The AXP represents advanced stem cell technology and India is one of the largest and fastestgrowing markets in the world,” said Vikram Karnani, vice president, Therapeutics, for Fenwal.
We look forward to working with ThermoGenesis to introduce this important technology to physicians in India.”
Engle noted that the AXP approval in India comes as the Company awaits approval of the product in China. “As we announced in October, the submission has been accepted by the Chinese Food & Drug Administration (SFDA), which represents successful completion of product testing and the administrative acceptance of the submission. The final professional
review is now in process and we are hopeful that the AXP will receive regulatory approval in China in early 2012.”

== Thermogenesis (KOOL) == HeinrichSchnitzel
HeinrichSchni.:

Thermogenesis Signs Worldwide...

 
10.01.12 18:47
#2
Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications

 

 

 

 

RANCHO CORDOVA, Calif.Jan. 10, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store human cell concentrates, said today it has entered into a five year collaboration with Arthrex, Inc., under which Arthrex will market ThermoGenesis' Res-Q® 60 (Res-Q) System technology for use in the preparation of autologous Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC).

Based in Naples, Florida, Arthrex is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. The company has developed more than 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures used worldwide.

The Res-Q technology is a point-of-care platform designed for the preparation of cell concentrates. In June, 2011, the Company received FDA clearance of its 510(k) submission for use of Res-Q technology for the safe and rapid preparation of autologous PRP from a small sample of blood. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.

About Arthrex

Arthrex, headquartered in Naples, FL, is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. More than 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures have been developed by Arthrex and are currently marketed worldwide. For more information, visit www.arthrex.com.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products.

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

 

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

 

 

SOURCE ThermoGenesis Corp.


© 2012 PR Newswire

== Thermogenesis (KOOL) == HeinrichSchnitzel

Hier der Chart nach News

 
#3

profichart.godmode-trader.de/1058002" style="max-width:560px" />



Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen
--button_text--